Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

DXCM vs ZBH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DXCM Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 7–3 Matrix Metrics)

DXCM Overall Winner 6-Pillar Tally: DXCM 4 – 2 ZBH Matrix Metrics: DXCM 7 – 3 ZBH

As of Nov 20, 2026, DexCom, Inc. (DXCM) is the stronger overall head-to-head candidate over Zimmer Biomet Holdings, Inc. (ZBH) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). DXCM carries a Unified Composite Score of 50.8/100 (HOLD) at $79.32 (25.3x Forward P/E, 24.0% operating margin), whereas ZBH carries 46.6/100 (HOLD) at $101.10 (11.3x Forward P/E, 16.7% operating margin).

  • Technical & Structure Timing Caution: DXCM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.0); meanwhile ZBH trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 51.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DXCM vs ZBH
DXCM NASDAQ Head-to-Head Winner
DexCom, Inc.
Surgical & Medical Instruments & Apparatus
$79.32
-1.08% 1D
Market Cap $29.9B
TTM Revenue $5.10B
Forward P/E 25.3x
Beta / 30D Vol 0.59β · 43% Vol
Unified Composite Score
50.8 / 100 HOLD
Tech 49.0 Fund 56.0 Flow 68.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.3%), weak momentum, RSI 43
RSI-14: 43.0 · SMA20: $81.49 · SMA50: $83.94
ZBH NYSE
Zimmer Biomet Holdings, Inc.
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$101.10
-0.36% 1D
Market Cap $19.2B
TTM Revenue $8.57B
Forward P/E 11.3x
Beta / 30D Vol 0.40β · 54% Vol
Unified Composite Score
46.6 / 100 HOLD
Tech 36.0 Fund 48.0 Flow 65.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.4% over 20 days), RSI 51
RSI-14: 51.0 · SMA20: $101.96 · SMA50: $96.50

6-Pillar Scorecard Institutional Category Breakdown (DXCM 4 – 2 ZBH)

Columns: Metric · DXCM · ZBH
1. Valuation Multiples ZBH
Forward P/E 25.3x 11.3x
Trailing P/E 31.6x 25.6x
PEG Ratio 1.30x 2.17x
EV / Revenue 5.9x 3.1x
2. Growth & Scale DXCM
Revenue Growth (YoY) +11.2% +3.1%
Earnings Growth (YoY) +2.6% -13.8%
TTM Revenue (USD) $5.10B $8.57B
Market Cap $29.9B $19.2B
3. Profitability & Quality DXCM
Gross Margin 63.4% 69.3%
Operating Margin 24.0% 16.7%
Net Profit Margin 19.4% 8.9%
Return on Equity (ROE) 37.7% 6.0%
4. Balance Sheet & Cash Flow DXCM
Cash Generation (TTM) $1.73B $1.51B
Cash Flow Margin 33.9% 17.6%
Net Cash / Leverage $432M Net Debt (0.55x D/E) $7.10B Net Debt (0.59x D/E)
Dividend Yield None (0.00%) 0.93%
5. Options & Positioning DXCM
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 63.0% (15th %ile) 133.3% (100th %ile)
Put/Call OI Skew 0.48x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat ZBH
OpEx & R&D Intensity 39.4% of Rev ($2.01B) 52.6% of Rev ($4.51B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Scale & Operating Efficiency Moat
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DXCM (7) vs ZBH (3)
Institutional Metric DXCM ZBH Criterion Row Edge
Market Capitalization
Scale
$29.9B $19.2B Larger Scale DXCM
Trailing P/E Ratio
Valuation
31.6x 25.6x Lower Multiple ZBH
Forward P/E Ratio
Valuation
25.3x 11.3x Lower Multiple ZBH
Revenue Growth (YoY)
Growth
+11.2% +3.1% Higher Growth DXCM
Operating Margin (TTM)
Profitability
24.0% 16.7% Higher Margin DXCM
Net Profit Margin
Profitability
19.4% 8.9% Higher Margin DXCM
Return on Equity (ROE)
Capital Efficiency
37.7% 6.0% Higher ROE DXCM
52-Week Range Position
Momentum
63% ($57–$93) 66% ($79–$113) Stronger Trend ZBH
Beta / 30D Volatility
Risk Regime
0.59β · 43% Vol 0.40β · 54% Vol Lower Realized Risk DXCM
Unified Institutional Score
Composite Signal
50.8 / 100 (HOLD) 46.6 / 100 (HOLD) Higher Composite DXCM
Trailing 12M Revenue (USD)
Operating Scale
$5.10B $8.57B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
63.4% 69.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.30x PEG · 5.9x EV/Rev 2.17x PEG · 3.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$1.73B ($432M Net Debt (0.55x D/E)) $1.51B ($7.10B Net Debt (0.59x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ZBH +1.04 pp
DXCM: +1.28% · ZBH: +2.32%
3M Horizon ZBH +13.01 pp
DXCM: -12.89% · ZBH: +0.12%
6M Horizon ZBH +8.24 pp
DXCM: +10.01% · ZBH: +18.25%
1Y Horizon DXCM +19.78 pp
DXCM: +32.8% · ZBH: +13.02%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period DXCM Revenue ZBH Revenue DXCM Op. Margin ZBH Op. Margin Margin Leader
FY2018 $1.03B $7.93B -18.1% 0.4% ZBH
FY2019 $1.48B $7.98B 9.6% 14.3% ZBH
FY2020 $1.93B $6.13B 15.5% 1.4% DXCM
FY2021 $2.45B $6.83B 10.9% 12.6% ZBH
FY2022 $2.91B $6.94B 13.4% 10.0% DXCM
FY2023 $3.62B $7.39B 16.5% 17.3% ZBH
FY2024 $4.03B $7.68B 14.9% 16.7% ZBH
FY2025 $4.66B $8.23B 19.6% 13.3% DXCM

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DXCM CONSOLIDATION
73d in phase · OBV ACCUMULATION
Current IV 63.0%
IV Percentile 15th %ile
Put/Call OI Skew 0.48x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact DXCM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ZBH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 133.3%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ZBH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $81.61 · IV 39.6%

DXCM vs. ZBH: Simulated 5-Day Option Payoffs & Capital Efficiency

Compare 100 shares of DXCM ($8,161) vs. ZBH ($10,141) against risk-defined 5-day vertical and put-wall option structures.

DXCM Spot $81.61 · IV 39.6%
DXCM Options Simulator →
5-DAY BULLISH SWING Liq B

Dec 18 $80 / $90 Bull Call Spread

Buy 1x $80C · Sell 1x $90C · 31d

Net Entry $482 Debit
T+5d @ +5% Move +$136 (+28%)
Max Risk / Buffer $482 Capped
5d Edge & Liquidity 0.7x R:R · Liq B
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq B

Dec 18 $75 / $70 Bull Put Spread

Sell 1x $75P · Buy 1x $70P · 31d

Net Entry $86 Credit
Max Credit / Yield +$86 (+20.8% RoM)
Max Risk / Buffer -9.2% Cushion ($414 Mgn)
5d Edge & Liquidity 78% PoP · Liq B
Simulate 5-Day Payoff →
ZBH Spot $101.41 · IV 34.7%
ZBH Options Simulator →
PUT-WALL MONTHLY INCOME Liq C

Dec 18 $95 / $90 Bull Put Spread

Sell 1x $95P · Buy 1x $90P · 31d

Net Entry $69 Credit
Max Credit / Yield +$69 (+16.0% RoM)
Max Risk / Buffer -7.0% Cushion ($431 Mgn)
5d Edge & Liquidity 79% PoP · Liq C
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD Liq C

Dec 18 $100 / $95 Bear Put Spread

Buy 1x $100P · Sell 1x $95P · 31d

Net Entry $170 Debit
T+5d @ -5% Drop +$108 (+63%)
Max Risk / Buffer $170 Capped
5d Edge & Liquidity 1.0x R:R · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DXCM Moat Profile High-Margin Pricing Power Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $29.9B market capitalization and 24.0% operating margin.
OpEx & R&D Reinvestment 39.4% of Rev ($2.01B)
90D Engineering Disclosures 0 Published
ZBH Moat Profile Scale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $19.2B market capitalization and 16.7% operating margin.
OpEx & R&D Reinvestment 52.6% of Rev ($4.51B)
90D Engineering Disclosures 0 Published

Investor FAQ DXCM vs ZBH Key Questions & Quantitative Answers

As of Nov 20, 2026, DexCom, Inc. (DXCM) is the stronger overall head-to-head candidate over Zimmer Biomet Holdings, Inc. (ZBH) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). DXCM carries a Unified Composite Score of 50.8/100 (HOLD) at $79.32 (25.3x Forward P/E, 24.0% operating margin), whereas ZBH carries 46.6/100 (HOLD) at $101.10 (11.3x Forward P/E, 16.7% operating margin). Technical & Structure Timing Caution: DXCM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.0); meanwhile ZBH trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 51.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DXCM leads the Growth & Scale pillar: DXCM posts +11.2% YoY revenue growth and +2.6% YoY earnings growth on $5.10B TTM revenue (63.4% gross margin, 24.0% operating margin), compared with ZBH at +3.1% YoY revenue growth and -13.8% YoY earnings growth on $8.57B TTM revenue (69.3% gross margin, 16.7% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), DXCM cumulative revenue shifted +352.4% while ZBH shifted +3.8%. In operating R&D and SG&A reinvestment, DXCM deploys 39.4% of Rev ($2.01B) (0 90-day corporate R&D disclosures) versus 52.6% of Rev ($4.51B) (0 disclosures) for ZBH.

ZBH screens cheaper on headline valuation multiples. DXCM trades at 25.3x Forward P/E, 31.6x Trailing P/E, 1.30x PEG, and 5.9x EV/Revenue (33.9% FCF margin), whereas ZBH trades at 11.3x Forward P/E, 25.6x Trailing P/E, 2.17x PEG, and 3.1x EV/Revenue (17.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DXCM (37.7% ROE) versus ZBH (6.0% ROE) capital efficiency.

In options market volatility and institutional positioning, DXCM carries 63.0% implied volatility (15th %ile, Compressed (<25th %ile)), a 0.48x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.59β · 43% Vol realized risk). By comparison, ZBH carries 133.3% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.40β · 54% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.